Iloperidone - Generic Drug Details

What are the generic drug sources for iloperidone and what is the scope of patent protection?

Iloperidone is the generic ingredient in two branded drugs marketed by Vanda Pharms Inc, Inventia, Lupin Ltd, and Taro, and is included in four NDAs. There are eight patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Iloperidone has fifty-nine patent family members in eight countries.

There are eight drug master file entries for iloperidone. Two suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for iloperidone

International Patents:	59
US Patents:	8
Tradenames:	2
Applicants:	4
NDAs:	4
Drug Master File Entries:	8
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	87
Clinical Trials:	26
Patent Applications:	5,944
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for iloperidone
What excipients (inactive ingredients) are in iloperidone?	iloperidone excipients list
DailyMed Link:	iloperidone at DailyMed

Recent Clinical Trials for iloperidone

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Vanda Pharmaceuticals	PHASE2
Vanda Pharmaceuticals	PHASE3
Vanda Pharmaceuticals	PHASE1

See all iloperidone clinical trials

Generic filers with tentative approvals for ILOPERIDONE

Applicant	Application No.	Strength	Dosage Form
		10MG	TABLET;ORAL
		8MG	TABLET;ORAL
		6MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for iloperidone

Drug Class

Atypical Antipsychotic

Anatomical Therapeutic Chemical (ATC) Classes for iloperidone

N05AX	Other antipsychotics
N05A	ANTIPSYCHOTICS
N05	PSYCHOLEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for ILOPERIDONE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FANAPT	Tablets	iloperidone	1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg	022192	1	2013-05-06

US Patents and Regulatory Information for iloperidone

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-005	May 6, 2009		RX	Yes	No
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-003	May 6, 2009		RX	Yes	No
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-007	May 6, 2009		RX	Yes	No
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-006	May 6, 2009		RX	Yes	No

Expired US Patents for iloperidone

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-004	May 6, 2009
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-001	May 6, 2009
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-007	May 6, 2009
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-005	May 6, 2009

EU/EMA Drug Approvals for iloperidone

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Vanda Pharmaceuticals Ltd	Fanaptum	iloperidone	EMEA/H/C/004149Treatment of schizophrenia	Refused	no	no	no		2018-01-15

International Patents for iloperidone

Country	Patent Number	Title	Estimated Expiration
Spain	2673603
Japan	2012502105
European Patent Office	2416779	PROCEDE DE PREDICTION DE LA PREDISPOSITION A UNE ELONGATION DE L'INTERVAL QT BASE SUR LE GENE BAI3 OU DE CES PRODUITS (METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION BASED ON BAI3 GENE SEQUENCE OR PRODUCT THEREOF)
Hungary	E037724

ILOPERIDONE Market Dynamics and Financial Trajectory

Last updated: March 5, 2026

What is ILOPERIDONE?

Iloperidone is an atypical antipsychotic medication approved by the U.S. Food and Drug Administration (FDA) in 2009 for the treatment of schizophrenia. It is marketed under the brand name Fanapt by Vanda Pharmaceuticals. The drug acts as a dopamine D2 and serotonin 5-HT2A receptor antagonist, with high affinity for certain serotonergic receptors, influencing psychotic symptoms and side effect profiles.

Market Size and Growth Potential

Global Schizophrenia Drug Market

The schizophrenia therapeutics market was valued at approximately $7.2 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of around 4% from 2023 to 2030, reaching nearly $10 billion by 2030[1].

ILOPERIDONE-specific Market Penetration

Iloperidone constitutes a modest segment, primarily competing with established atypical antipsychotics like risperidone, olanzapine, and aripiprazole. Its market share remains limited, holding an estimated less than 2% of the global schizophrenia drug market in 2023.

Factors constraining its market share include:

• Competition from more established agents
• Limited clinical advantages
• Side effect profile concerns
• Patent expirations and generic competition

Pricing and Reimbursement

The average wholesale price (AWP) for iloperidone is approximately $100 per month per patient, similar to other second-generation antipsychotics. Reimbursement coverage varies across regions and insurance plans, influencing prescribing trends.

Market Dynamics

Competitive Landscape

Iloperidone faces competition from several drug classes:

• Second-generation antipsychotics: risperidone, olanzapine, quetiapine, aripiprazole
• Long-acting injectables (LAIs): paliperidone palmitate, risperidone LAI
• Novel agents and generics: improved formulations or patent expirations

Major pharmaceutical players include Johnson & Johnson, Novartis, and Otsuka Pharmaceutical, which dominate the market.

Therapeutic Positioning

Iloperidone's positioning emphasizes:

• Moderate efficacy
• Dizziness risk linked to orthostatic hypotension
• Favorable metabolic side effect profile compared to olanzapine

However, its side effect profile limits wider adoption. Clinicians favor medications with better tolerability and proven long-term outcomes.

Regulatory and Patent Status

The original patent protection for iloperidone expired in 2023 in major markets, opening the door for generic development. This may reduce drug costs but also diminish the revenue potential of the branded product.

Clinical Development and Off-label Use

Research continues into iloperidone for off-label indications such as bipolar disorder and psychosis in Parkinson’s disease, but these are not yet approved. Additional formulations or combination therapies under investigation could influence future market dynamics.

Financial Trajectory

Revenue Trends

Vanda Pharmaceuticals reported approximately $150 million in global sales of Fanapt in 2022. Sales have plateaued due to increased generic competition and market saturation.

Cost Structure and R&D Spending

• Development costs for new formulations or indications likely exceed $50 million.
• Market penetration efforts focus on clinician education and expanding access in emerging markets.

Future Revenue Projections

Given patent expiration and generic entry, revenue is expected to decline at a CAGR of -8% to -10% over the next five years[2].

Potential upside exists if:

• New formulations (e.g., extended-release versions) are developed.
• Additional indications receive regulatory approval.
• Market expansion occurs in developing economies with growing mental health burdens.

Key Market Drivers and Challenges

Drivers	Challenges
Increasing prevalence of schizophrenia	Competitive landscape dominated by entrenched drugs
Rising awareness and diagnosis access	Generic price erosion post-patent expiry
Expanded insurance coverage	Limited clinical differentiation from competitors
Development of novel formulations	Side effect profile concerns

Conclusion

Iloperidone's position in the schizophrenia therapeutic landscape remains modest. Its market prospects face pressure from generic competition and existing therapies with more established profiles. Potential growth hinges on optimizing formulations, expanding indications, and market penetration in emerging territories.

Key Takeaways

• Global schizophrenia drug market increased from $6.8 billion in 2021 to $7.2 billion in 2022.
• Iloperidone holds less than 2% of the market, with revenues around $150 million in 2022.
• Patent expiration in 2023 likely causes revenue decline, projected at -8% to -10% CAGR over five years.
• Market dynamics favor drugs with better tolerability profiles; iloperidone's side effects limit broader adoption.
• Future growth depends on new formulations, additional approvals, and market expansion.

FAQs

Q1: How does iloperidone compare to other atypical antipsychotics?
A: It offers moderate efficacy with a lower risk of metabolic side effects but has a higher incidence of orthostatic hypotension, affecting tolerability.

Q2: What is the impact of patent expiration on iloperidone's revenue?
A: Patent expiry in 2023 facilitates generic entry, significantly reducing branded sales and pressuring revenue.

Q3: Are there ongoing clinical trials for iloperidone?
A: Yes. Trials are investigating extended-release formulations and potential off-label uses such as bipolar disorder.

Q4: What are the main barriers to increased market share?
A: Competitive drugs with better side effect profiles, generic price erosion, and limited clinical advantages.

Q5: Which regions are most promising for expanding iloperidone sales?
A: Emerging markets in Asia and Latin America, where mental health treatment access improves and generic options are less prevalent.

---

References

[1] MarketWatch. (2023). Schizophrenia therapeutics market forecast.

[2] Vanda Pharmaceuticals. (2022). Annual Report.